Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell profiling of cutaneous T-cell lymphoma after treatment with vorinostat and photophoresis.

ABSTRACT: Single-cell profiling of cutaneous T-cell lymphoma after treatment with vorinostat and photophoresis.

PROVIDER: PRJNA514236 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8428606_1.fastq.gz	Fastqsanger.gz
	SRR8428606_2.fastq.gz	Fastqsanger.gz
	SRR8428607_1.fastq.gz	Fastqsanger.gz
	SRR8428607_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Development and characterization of vorinostat-resistant cutaneous T cell lymphoma cells

Project description:Development and characterization of vorinostat-resistant cutaneous T cell lymphoma cells

| PRJNA693837 | ENA

Single-cell profiling of cutaneous T-cell lymphoma after treatment with vorinostat and photophoresis.

Project description:Cutaneous T cell lymphomas (CTCL), encompassing a spectrum of T-cell lymphoproliferative disorders involving the skin, have collectively increased in incidence over the last 40 years. Sézary syndrome (SS) is an aggressive form of CTCL characterized by significant presence of malignant cells in both the blood and skin. The guarded prognosis for SS reflects a lack of reliably effective therapy, due in part to an incomplete understanding of disease pathogenesis. Using single-cell sequencing of RNA at the induction of vorinostat and photopherisis treatment (GSE122703) and at the progression on therapy. We identifed thea decrease conventional SS cell markers on therapy and an increase in the number of cells expressing FOXP3+.

2019-06-25 | GSE124898 | GEO

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Project description:This phase I trial studies the side effects and the best dose of alisertib when given together with vorinostat in treating patients with Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, or peripheral T-cell lymphoma that has come back. Alisertib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

| 2123001 | ecrin-mdr-crc

Gene expression profiles of Hodgkin’s lymphoma cells after treatment with vorinostat

Project description:By using high-density DNA microarrays, we analyzed the gene-expression profile of Hodgkin's lymphoma cell line L-540 after tretament with the histone deactelyse inhibitor vorinostat. Kewitz et al., submitted RNA was extracted from established Hodgkin's lymphoma cell line L-540 and hybridized with Affymetrix HG_U133A microarrays.

2011-12-31 | E-GEOD-30884 | biostudies-arrayexpress

Gene expression profiles of Hodgkin’s lymphoma cells after treatment with vorinostat

2011-12-31 | GSE30884 | GEO

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

Project description:RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, and may stimulate the immune system to stop cancer cells from growing. PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat after stem cell transplant in treating patients with high-risk lymphoma.

| 2046609 | ecrin-mdr-crc

Study of cutaneous biology of cutaneous T cell lymphoma

Project description:Study of cutaneous biology of cutaneous T cell lymphoma

| PRJNA785680 | ENA

Study of cutaneous biology of cutaneous T cell lymphoma

Project description:Study of cutaneous biology of cutaneous T cell lymphoma

| PRJNA785707 | ENA

Development and characterization of vorinostat-resistant cutaneous T cell lymphoma cells

Project description:We demonstrate that vorinostat-resistant HuT78VR exhibits enhanced invasion characteristics and activation of MAPK signaling.

2021-01-22 | GSE165261 | GEO

Single-cell profiling of cutaneous T-cell lymphoma

Project description:Single-cell profiling of cutaneous T-cell lymphoma